Skip to main content

Table 3 Predicting future new onset HFpEF with five biomarkers

From: Biomarker profiling for risk of future heart failure (HFpEF) development

  Unadj. OR [95% CI] p Adj. OR [95% CI] p AUC
Gal3 Baseline 1.08 [0.99,1.18] ns 1.08 [0.97,1.21] ns 0.62 [0.50,0.74]
Gal3 Follow-up 1.15 [1.03,1.28] 0.011 1.17 [1.02,1.34] 0.027 0.67 [0.55,0.78]
Gal3 delta 1.04 [0.90,1.22] ns 1.32 [1.04,1.67] 0.024 0.63 [0.50,0.76]
sST2 Baseline 1.04 [0.98,1.09] ns 1.06 [1.00,1.13] ns 0.56 [0.43,0.69]
sST2 Follow-up 1.03 [0.99,1.08] ns 1.03 [0.97,1.08] ns 0.55 [0.43,0.67]
sST2 delta 1.03 [0.95,1.11] ns 1.01 [0.93,1.10] ns 0.51 [0.37,0.65]
IL6 Baseline 1.28 [0.91,1.80] ns 1.28 [0.89,1.85] ns 0.62 [0.50,0.74]
IL6 Follow-up 1.08 [0.78,1.49] ns 1.11 [0.72,1.71] ns 0.61 [0.49,0.73]
IL6 delta 0.81 [0.56,1.16] ns 0.76 [0.51,1.14] ns 0.54 [0.40,0.68]
hsTropI Baseline 1.19 [1.03,1.38] 0.017 1.21 [1.04,1.42] 0.017 0.62 [0.49,0.76]
hsTropI Follow-up 1.19 [1.03,1.37] 0.016 1.07 [0.93,1.22] ns 0.65 [0.53,0.77]
hsTropI delta 1.14 [0.92,1.40] ns 1.07 [0.85,1.35] ns 0.58 [0.44,0.72]
ln(BNP) Baseline 2.85 [1.62,5.02]  < .001 2.71 [1.47,5.01] 0.001 0.74 [0.63,0.86]
ln(BNP) Follow-up 5.16 [2.34,11.4]  < .001 5.13 [2.14,12.3]  < .001 0.81 [0.71,0.90]
ln(BNP) delta 1.58 [0.79,3.16] ns 1.70 [0.79,3.64] ns 0.58 [0.45,0.71]
All markers model—Baseline 0.82 [0.73,0.92]
All markers model—Follow-up 0.86 [0.79,0.94]
All markers model—delta 0.68 [0.55,0.81]
  1. Adj. OR Odds Ratio Adjusted for all other biomarkers at corresponding time-point, Gal3 Galectin-3, sST2 soluble suppression of tumorigenicity 2, IL6 interleuckin 6, hsTroponin high sensitivity troponin I, BNP b-type natriuretic peptide